DK1503759T3 - Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf - Google Patents
Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser herafInfo
- Publication number
- DK1503759T3 DK1503759T3 DK03726824T DK03726824T DK1503759T3 DK 1503759 T3 DK1503759 T3 DK 1503759T3 DK 03726824 T DK03726824 T DK 03726824T DK 03726824 T DK03726824 T DK 03726824T DK 1503759 T3 DK1503759 T3 DK 1503759T3
- Authority
- DK
- Denmark
- Prior art keywords
- derivatives
- carboxylic acids
- sub
- site
- action
- Prior art date
Links
- -1 quinolone carboxylic acids Chemical class 0.000 title abstract 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 8
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 4
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38064102P | 2002-05-14 | 2002-05-14 | |
| PCT/US2003/014948 WO2003097564A2 (en) | 2002-05-14 | 2003-05-12 | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1503759T3 true DK1503759T3 (da) | 2009-04-14 |
Family
ID=29549994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03726824T DK1503759T3 (da) | 2002-05-14 | 2003-05-12 | Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7355047B2 (enExample) |
| EP (1) | EP1503759B1 (enExample) |
| JP (1) | JP4532263B2 (enExample) |
| KR (1) | KR20040107525A (enExample) |
| CN (1) | CN1652784A (enExample) |
| AT (1) | ATE417613T1 (enExample) |
| AU (1) | AU2003229043B2 (enExample) |
| BR (1) | BR0309965A (enExample) |
| CA (1) | CA2484308A1 (enExample) |
| DE (1) | DE60325347D1 (enExample) |
| DK (1) | DK1503759T3 (enExample) |
| ES (1) | ES2319176T3 (enExample) |
| IL (1) | IL164734A0 (enExample) |
| MX (1) | MXPA04011156A (enExample) |
| NZ (1) | NZ536061A (enExample) |
| WO (1) | WO2003097564A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2484308A1 (en) * | 2002-05-14 | 2003-11-27 | The Regents Of The University Of California | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
| US7470706B2 (en) | 2004-01-31 | 2008-12-30 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| DE102004004971B3 (de) * | 2004-01-31 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel |
| UA85711C2 (ru) * | 2004-05-06 | 2009-02-25 | Зе Регентс Оф Зе Юниверсити Оф Калифорния | Замещенные енаминоны, их производные и их применение |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| CN101891680B (zh) | 2004-06-24 | 2014-10-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
| MX2007012335A (es) * | 2005-04-11 | 2007-11-21 | Hoffmann La Roche | (3,4-dihidro-quinazolina-2-il)-indano-1-il-aminas. |
| MX2007013606A (es) * | 2005-05-04 | 2007-12-10 | Hoffmann La Roche | (3,4-dihidro-quinazolin2-il)-(2-ariloxi-etil)-aminas que tienen una actividad en el receptor 5-ht. |
| ATE475650T1 (de) * | 2005-12-05 | 2010-08-15 | Merck Sharp & Dohme | Positive allosterische chinolon-m1- rezeptormodulatoren |
| CN101374849A (zh) * | 2005-12-24 | 2009-02-25 | 沃泰克斯药物股份有限公司 | 作为abc转运蛋白调控剂的喹啉-4-酮衍生物 |
| DK3219705T3 (da) | 2005-12-28 | 2020-04-14 | Vertex Pharma | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid |
| WO2007106537A2 (en) * | 2006-03-13 | 2007-09-20 | Activx Biosciences, Inc. | Aminoquinolones as gsk-3 inhibitors |
| EP1886996A1 (en) * | 2006-08-10 | 2008-02-13 | Ferrer Internacional, S.A. | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions |
| KR20090035744A (ko) * | 2006-08-10 | 2009-04-10 | 페레르 인터내쇼날 에스.에이. | Ｇａｂａ 수용체의 친화력을 갖는 1ｈ-퀴놀린-4-원 화합물,제조방법, 사용방법 및 조성물 |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| ES2399071T3 (es) | 2006-10-16 | 2013-03-25 | Bionomics Limited | Nuevos compuestos ansiolíticos |
| WO2009040377A2 (en) * | 2007-09-27 | 2009-04-02 | Ge Healthcare Limited | Imaging agents |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| AU2009307892A1 (en) * | 2008-10-23 | 2010-04-29 | Merck Sharp & Dohme Corp. | Fused heterocyclic M1 receptor positive allosteric modulators |
| KR101727762B1 (ko) | 2009-03-20 | 2017-04-17 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
| US20120093917A1 (en) * | 2009-04-02 | 2012-04-19 | Robert Hromas | Metnase and intnase inhibitors and their use in treating cancer |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| JP2014510065A (ja) | 2011-03-02 | 2014-04-24 | バイオノミックス リミテッド | 治療薬としての新規な小分子 |
| WO2012116410A1 (en) * | 2011-03-02 | 2012-09-07 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
| JP6055817B2 (ja) | 2011-05-12 | 2016-12-27 | バイオノミックス リミテッド | ナフチリジンの調製方法 |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| CN107501107A (zh) * | 2017-09-26 | 2017-12-22 | 兰亚朝 | 喹诺酮药物的中间体合成方法 |
| CN111269131B (zh) * | 2020-03-12 | 2021-12-28 | 江苏飞宇医药科技股份有限公司 | 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1433774A (en) * | 1973-02-26 | 1976-04-28 | Allen & Hanburys Ltd | Heterocyclic compounds apparatus for conveying articles |
| JPS5715760B2 (enExample) * | 1974-06-11 | 1982-04-01 | ||
| US4390541A (en) | 1980-12-19 | 1983-06-28 | Lilly Industries Limited | Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease |
| US6248739B1 (en) * | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
| WO2000068202A1 (en) | 1999-05-06 | 2000-11-16 | Neurogen Corporation | Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands |
| GB0127349D0 (en) * | 2001-11-14 | 2002-01-02 | Glaxo Group Ltd | Macrolides |
| CA2484308A1 (en) * | 2002-05-14 | 2003-11-27 | The Regents Of The University Of California | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
-
2003
- 2003-05-12 CA CA002484308A patent/CA2484308A1/en not_active Abandoned
- 2003-05-12 KR KR10-2004-7018340A patent/KR20040107525A/ko not_active Ceased
- 2003-05-12 AT AT03726824T patent/ATE417613T1/de not_active IP Right Cessation
- 2003-05-12 DE DE60325347T patent/DE60325347D1/de not_active Expired - Lifetime
- 2003-05-12 US US10/514,808 patent/US7355047B2/en not_active Expired - Fee Related
- 2003-05-12 DK DK03726824T patent/DK1503759T3/da active
- 2003-05-12 ES ES03726824T patent/ES2319176T3/es not_active Expired - Lifetime
- 2003-05-12 BR BR0309965-2A patent/BR0309965A/pt not_active IP Right Cessation
- 2003-05-12 AU AU2003229043A patent/AU2003229043B2/en not_active Ceased
- 2003-05-12 JP JP2004505299A patent/JP4532263B2/ja not_active Expired - Fee Related
- 2003-05-12 WO PCT/US2003/014948 patent/WO2003097564A2/en not_active Ceased
- 2003-05-12 EP EP03726824A patent/EP1503759B1/en not_active Expired - Lifetime
- 2003-05-12 CN CNA03810816XA patent/CN1652784A/zh active Pending
- 2003-05-12 NZ NZ536061A patent/NZ536061A/en unknown
- 2003-05-12 MX MXPA04011156A patent/MXPA04011156A/es active IP Right Grant
-
2004
- 2004-10-20 IL IL16473404A patent/IL164734A0/xx unknown
-
2008
- 2008-02-15 US US12/032,403 patent/US20080176897A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1503759A4 (en) | 2006-02-15 |
| AU2003229043A1 (en) | 2003-12-02 |
| WO2003097564A3 (en) | 2004-02-26 |
| US20060178516A1 (en) | 2006-08-10 |
| ES2319176T3 (es) | 2009-05-05 |
| BR0309965A (pt) | 2005-03-01 |
| US7355047B2 (en) | 2008-04-08 |
| WO2003097564A2 (en) | 2003-11-27 |
| IL164734A0 (en) | 2005-12-18 |
| JP2005535592A (ja) | 2005-11-24 |
| CN1652784A (zh) | 2005-08-10 |
| JP4532263B2 (ja) | 2010-08-25 |
| NZ536061A (en) | 2008-09-26 |
| ATE417613T1 (de) | 2009-01-15 |
| HK1072905A1 (en) | 2005-09-16 |
| EP1503759A2 (en) | 2005-02-09 |
| DE60325347D1 (de) | 2009-01-29 |
| EP1503759B1 (en) | 2008-12-17 |
| US20080176897A1 (en) | 2008-07-24 |
| MXPA04011156A (es) | 2005-02-17 |
| CA2484308A1 (en) | 2003-11-27 |
| KR20040107525A (ko) | 2004-12-20 |
| AU2003229043B2 (en) | 2008-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL164734A0 (en) | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof | |
| ATE370943T1 (de) | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren | |
| NO2014005I1 (no) | olodaterol, syreaddisjonssalter og farmakologisk akseptable syrer derav | |
| NO20081755L (no) | Modifiserte proteaser som inhiberer komplementaktivering | |
| ATE380175T1 (de) | Pyrrolidine als dipeptidyl peptidase inhibitoren | |
| NO20072767L (no) | Gabapentin prodrug vedvarende frigivelse orale doseringsformer | |
| NO20055370D0 (no) | Alfa-substituert karboksylsyre som PPAR modulatorer | |
| DK1347955T3 (da) | Nye mandelsyrederivater og deres anvendelse som throbin-hæmmere | |
| WO2004045520A3 (en) | Complement receptor 2 targeted complement modulators | |
| EA200600203A1 (ru) | Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2 | |
| DK0946176T3 (da) | Anvendelse af 7-(2-oxa-5,8-diazabicyclo[4.3.0]quinoloncarboxylsyre- og naphthydridoncarboxylsyrederivater til fremstilling af et lægemiddel til behandling af Helicobacter-pylori-infektioner og dermed associerede gastroduodenale sygdomme | |
| DK1311256T3 (da) | Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser | |
| DK0678087T3 (da) | Forbindelser med selektiv aktivitet til retinoid-X-receptorer og metoder til modulering af processer medieret af retinoid-X | |
| DE60235212D1 (de) | Fluoropyrrolidine als Dipeptidylpeptidasehemmer | |
| UA85597C2 (ru) | Четвертичные соли как антагонисты ccr2 | |
| PT1140945E (pt) | Derivados 1 2 4 tiadiazina fundidos a sua preparacao e a sua utilizacao | |
| EA200600735A1 (ru) | Нуклеиновые кислоты, специфично связывающие биоактивный грелин | |
| AU2003293311A8 (en) | Secondary binding site of dipeptidyl peptidase iv (dp iv) | |
| ATE273288T1 (de) | 2,3,4,5-tetrahydro-1h-(1,4)benzodiazepin-3- hydroxamsäure als matrix metalloproteinaseinhibitoren | |
| DK1429807T3 (da) | Kombination af et NSAID og en PDE4-inhibitor | |
| FR2809595B1 (fr) | Derive laitier presentant une composition minerale et en acides amines selectivement modifiee, procedes pour sa fabrication, et utilisation. | |
| DK1476470T3 (da) | Stivelsesderivater, stivelse-aktivstof-konjugater, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemidler | |
| NO20056161L (no) | Formuleringer for behandling av artrittilstander | |
| DE60216641D1 (de) | Polymorph von 4-ä2-ä4-ä1-(2-ethoxyethyl)-1h-benzimidazol-2-ylü-1-piperidinylüethylü-alpha, alpha-dimethylbenzolessigsäure | |
| UA85711C2 (ru) | Замещенные енаминоны, их производные и их применение |